Wolfram P. Kastner und Martin Krenn,
Schwere Sachbeschädigung – oder notwendige Ergänzung eines gefälschten Zitats?
Die Republik Österreich, Landesgericht Salzburg, hat gegen den Künstler Wolfram P. Kastner, der zusammen mit Martin Krenn eine Klasse an der Sommerakademie für Bildende Kunst 2001 leitete, ein Strafverfahren wegen „schwerer Sachbeschädigung“ eingeleitet und ein deutsches Amtsgericht um Amtshilfe und „Abhörung“ ersucht.
Was ist der Grund?
Der Begründer des Zionismus, Dr. Theodor Herzl, der sein Rechtsreferendariat am Salzburger Landesgericht ableistete, schrieb in sein Tagebuch: „In Salzburg brachte ich einige der glücklichsten Stunden meines Lebens zu. Ich wäre auch gerne in dieser schönen Stadt geblieben, aber als Jude wäre ich nie zur Stellung eines Richters befördert worden.“
Die Stadt Salzburg brachte im Jahr 2001 dort eine Marmortafel mit dem sinnentstellend verkürzten Zitat an: „In Salzburg brachte ich einige der glücklichsten Stunden meines Lebens zu.“
Am 29. August 2001 nahmen Wolfram P. Kastner und Martin Krenn mit den Studierenden in aller Öffentlichkeit eine handschriftliche Vervollständigung des Zitats vor. Sie sahen darin eine „Rückgabe der unterschlagenen Worte“, in der Hoffnung, daß dies die Verantwortlichen dazu bewegen könnte, ihren Fehler zu erkennen und zu verbessern.
Martin Krenn: „Die Tendenz zur Kriminalisierung von politischen Aktionen und die Einschränkung der künstlerischen Freiheit nimmt in Österreich bedauerlicher Weise zu. Aus meiner Sicht muß dem entschieden entgegen getreten werden.“
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
Symptoms improved significantly in adults with the bleeding disorder hemophilia B following a single treatment with gene therapy developed by researchers at St. Jude Children’s Research Hospital in Memphis and demonstrated to be safe in a clinical trial conducted at the University College London (UCL) in the U.K.
The findings of the six-person study mark the first proof that gene therapy can reduce disabling, painful bleeding episodes in patients with the inherited blood disorder. Results of the Phase I study appear in the December 10 online edition of the New England Journal of Medicine. The research is also scheduled to be presented December 11 at the 53rd annual meeting of the American Society of Hematology in San Diego.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46766-st-jude-children-s-research-hospital-gene-therapy-bleeding-disorder
St. Jude Children’s Research Hospital is naming the institution’s principal research tower after Donald Pinkel, M.D., whose legacy of driving progress toward advancing cures for pediatric catastrophic diseases continues at the institution today.
When St. Jude was established 55 years ago, Pinkel, the hospital’s first medical director, committed to finding cures for childhood cancer, leading to groundbreaking treatments that saved countless children’s lives. Many of these cancers were deemed incurable prior to Pinkel’s research, but his distinct approach to eradicating diseases established a model for how cancers could be treated.
To view the multimedia release go to:
https://www.multivu.com/players/English/7924752-st-jude-childrens-research-hospital-donald-pinkel-tower/
The most detailed analysis yet of the role germline mutations in genes associated with cancer predisposition play in the development of childhood cancer suggests that comprehensive genomic screening may be warranted on all pediatric cancer patients, not just those with a family history of cancer. The study from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project appears in the November 19 edition of the New England Journal of Medicine.
Ultimately, researchers anticipate that systematic monitoring of patients and family members who have germline mutations in cancer predisposition genes will allow the detection of cancers at their earliest and most curable stage, thereby improving the outcomes for these children and family members.
To view the multimedia release go to:
http://www.multivu.com/players/English/7692851-st-jude-hospital-genome-project/
Ganador del GRAMMY® Latino, Luis Fonsi y la actriz ganadora de premios Emmy® y Golden Globe, Sofia Vergara, se unen a personalidades y artistas importantes para apoyar la campaña Thanks and Giving de St. Jude. La campaña, ahora en su noveno año, pide a los consumidores que agradezcan la salud de sus niños y ayuden a aquellos que no la tienen apoyando la misión de St. Jude.
Para más información, vaya a http://www.multivu.com/mnr/58261-st-jude-la-campana-thanks-and-giving
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children’s Research Hospital scientists have created the world’s largest collection of pediatric solid tumor samples, drug-sensitivity data and related information and have made the resource available at no charge to the global scientific community.
St. Jude and the Howard Hughes Medical Institute collaborated to create the resource, known as the Childhood Solid Tumor Network. The work is reported today as an advance online publication in the scientific journal Nature.
“Survival rates for children with recurrent solid tumors have not improved significantly in more than 20 years and remain below 30 percent,” said corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. “This research will change that by promoting scientific collaboration to leverage the efforts of researchers worldwide to advance understanding and ultimately treatment of pediatric solid tumors.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8121952-st-jude-childrens-childhood-solid-tumor-network/
http://www.charity4couture.com Hello
Lovelies! I’m Nancy Li, founder of Charity4Couture; a nonprofit
organization that takes donated clothes, refurbishes them (such as
studding, cutting, sewing, etc.), and then sells them on my website.
Best of all, proceeds will be donated directly to St.Jude\\\'s Research
Hospital and the Hirshberg Foundation.
http://www.indiegogo.com/fundcharity4couture
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
